Hostname: page-component-7479d7b7d-qs9v7 Total loading time: 0 Render date: 2024-07-12T12:47:37.628Z Has data issue: false hasContentIssue false
  • English
  • Français

“Inducing a Miscarriage”: Women-Centered Perspectives on RU 486/Prostaglandin as an Early Abortion Method

Published online by Cambridge University Press:  29 April 2021

Marge Berer
Get access Rights & Permissions [Opens in a new window]

Extract

In countries where abortion is performed safely in medical settings, the vast majority of up to several generations of women have come to identify early abortion as a surgical experience—whether on an inpatient or outpatient basis, whether with local or general anesthetic or whether in a freestanding clinic or a hospital.

In this context, the introduction of RU 486 with prostaglandin (RU 486/PG) as an alternative method of early abortion will once more alter women's experience of abortion.

The first part of this paper explores the similarities and differences between an abortion with RU 486/PG and vacuum aspiration from a women-centered perspective. This comparison is limited by the fact that only women in France have so far had access to both methods, along with those who have participated in clinical trials, and that very few in-depth women's experiences and reactions to this method have been published.

Type
Patient Perspectives
Information
Law, Medicine and Healthcare , Volume 20 , Issue 3 , Fall 1992 , pp. 199 - 208
Copyright
© 1992 American Society of Law, Medicine & Ethics

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Birman, Chantal, “The Experiences of Women Having an Abortion with RU 486,” paper included in a press packet on RU 486 by the Union Suisse Pour le Decriminalisation de l'Avortement, Switzerland, April 1989, summarized in English in WGNRR Newsletter 31, October-December 1989:7–9.Google Scholar
“I tested the RU 486 pill”, Medecine et Hygiene 8 Nov 1988.Google Scholar
Parsons, Tony, “The Potential for the Private Sector”, In: The Abortion Pill: Widening the Choice for Women, (London: The Birth Control Trust, 1990) pp. 48–51.Google Scholar
Templeton, Allan, “How Women Respond to Mifepristone: Results of the Clinical Trials”, In: The Abortion Pill: Widening the Choice for Women, (London: The Birth Control Trust, 1990) pp. 22–28.Google Scholar
Paintin, David, “The Organisation of the Use of Mifepristone for Pregnancy Termination,” In: The Abortion Pill: Widening the Choice for Women, (London: The Birth Control Trust, 1990) pp. 36–40.Google Scholar
Bureau, Annie, “Clinical Results of a Trial with RU 486 and a Prostaglandin Injection (Nalador)”, paper included in a press packet on RU 486 by the Union Suisse Pour le Decriminalisation de l'Avortement, Switzerland, April 1989, summarized in English in WGNRR Newsletter as above; see also note 1, supra.Google Scholar
Supra note 1.Google Scholar
A.K., personal communication, 1991.Google Scholar
Supra note 6.Google Scholar
Supra note 4.Google Scholar
Supra note 1.Google Scholar
Rademakers, Jany, personal communication, 1989.Google Scholar
U.K. Department of Health, Daycare Treatment for Medical Termination of Early Pregnancy, (London, 1991.)Google Scholar
Brady, Martha, “Medical Abortifacients: A New Technology Requiring New Research”, paper presented at Abortion Research Methodology, New York, 12–13 December 1989, organized by The Population Council.Google Scholar
Aubény, Élisabeth, “New Perspective for Patients: Drug-induced Abortion by RU 486 and Prostaglandins”, paper presented at From Abortion to Contraception: Public Health Approaches to Reducing Unwanted Pregnancy and Abortion through Improved Family Planning Services, 10–13 October 1990, Tblisi, USSR.Google Scholar
Supra note 1.Google Scholar
Aubény, Élisabeth, paper presented at RU 486: The French Experience, 9–11 July, Washington, D.C., as reported by the Reproductive Health Technologies Project, organizers of the meeting; Supra note 15.Google Scholar
Supra note 15.Google Scholar
Supra note 13.Google Scholar
Supra note 1.Google Scholar
Riding, Alan, “Frenchwoman's death is linked to abortion pill and a hormone”, The New York Times, April 10, 1991.Google Scholar
Supra note 13.Google Scholar
Ibid.Google Scholar
Supra note 14.Google Scholar
Supra notes 15, 17.Google Scholar
Van Look, Paul, “The Use of RU 486 (Mifepristone) as a Medical Abortifacient: Current and Future Research Needs”, paper presented at Seminar on RU 486: The Abortion Pill, Wemos Women and Pharmaceuticals Project, April, 1990.Google Scholar
Supra notes 15, 17.Google Scholar
Supra note 21.Google Scholar
Lim, B.H. et al., “Normal Development after Exposure to Mifepristone in Early Pregnancy,” letter to The Lancet, 336 (28 July 1990): 257–258.Google Scholar
Saffron, Lisa, personal communication, 1991.Google Scholar
Supra note 6.Google Scholar
Raymond, Janice G. et al., RU 486: Misconceptions, Myths and Morals, (Cambridge, MA: Institute on Women & Technology, 1991.)Google Scholar
Lloyd, Ann, “RU Ready?” The Guardian, 1 May 1991.Google Scholar